RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD

References

• World Health Organization. WHO global report on trends in prevalence of tobacco use 2000–2025, third edition; 2019. Available from: https://www.who.int/publications/i/item/who-global-report-on-trends-in-prevalence-of-tobacco-use-2000-2025-third-edition. Accessed April 2023.
   Google Scholar
• Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med. 2022;10(5):497–511. doi:10.1016/S2213-2600(21)00506-3
   PubMed Web of Science ®Google Scholar
• Zbozinkova Z, Barczyk A, Tkacova R, et al. POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe. Int J Chron Obstruct Pulmon Dis. 2016;11:611–622. doi:10.2147/COPD.S88846
   PubMed Web of Science ®Google Scholar
• Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE study. Eur Respir J. 2017;49(5):1601446. doi:10.1183/13993003.01446-2016
   PubMed Web of Science ®Google Scholar
• Golpe R, Suárez-Valor M, Martín-Robles I, et al. Mortality in COPD patients according to clinical phenotypes. Int J Chron Obstruct Pulmon Dis. 2018;13:1433–1439. doi:10.2147/COPD.S159834
   PubMed Web of Science ®Google Scholar
• Brat K, Svoboda M, Zatloukal J, et al. The relation between clinical phenotypes, GOLD groups/stages and mortality in COPD patients–a prospective multicenter study. Int J Chron Obstruct Pulmon Dis. 2021;16:1171–1182. doi:10.2147/COPD.S297087
   PubMed Web of Science ®Google Scholar
• Hernández Vázquez J, Ali García I, Jiménez-García R, et al. COPD phenotypes: differences in survival. Int J Chron Obstruct Pulmon Dis. 2018;13:2245–2251. doi:10.2147/COPD.S166163
   PubMed Web of Science ®Google Scholar
• Rennard SI, Locantore N, Delafont B, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12(3):303–312. doi:10.1513/AnnalsATS.201403-125OC
   PubMed Web of Science ®Google Scholar
• Tiew PY, San Ko FW, Narayana JK, et al. “High-risk” clinical and inflammatory clusters in COPD of Chinese descent. Chest. 2020;158(1):145–156. doi:10.1016/j.chest.2020.01.043
   PubMed Web of Science ®Google Scholar
• Aramburu A, Arostegui I, Moraza J, et al. COPD classification models and mortality prediction capacity. Int J Chron Obstruct Pulmon Dis. 2019;14:605–613. doi:10.2147/COPD.S184695
   PubMed Web of Science ®Google Scholar
• Pikoula M, Quint JK, Nissen F, Hemingway H, Smeeth L, Denaxas S. Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records. BMC Med Inform Decis Mak. 2019;19(1):86. doi:10.1186/s12911-019-0805-0
   PubMedGoogle Scholar
• Burgel P-R, Paillasseur J-L, Janssens W, et al. A simple algorithm for the identification of clinical COPD phenotypes. Eur Respir J. 2017;50(5):1701034. doi:10.1183/13993003.01034-2017
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J. 2013;41(6):1252–1256. doi:10.1183/09031936.00118912
   PubMed Web of Science ®Google Scholar
• Gagatek S, Wijnant SRA, Stallberg B, et al. Validation of clinical COPD phenotypes for prognosis of long-term mortality in Swedish and Dutch cohorts. COPD. 2022;19(1):330–338. doi:10.1080/15412555.2022.2039608
   PubMedGoogle Scholar
• Kaur M, Chandel J, Malik J, Naura AS. Particulate matter in COPD pathogenesis: an overview. Inflam Res. 2022;71(7–8):797–815. doi:10.1007/s00011-022-01594-y
   PubMed Web of Science ®Google Scholar
• Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011;139(4):752–763. doi:10.1378/chest.10-1253
   PubMed Web of Science ®Google Scholar
• Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733–743. doi:10.1016/S0140-6736(09)61303-9
   PubMed Web of Science ®Google Scholar
• Agusti A, Vogelmeier C, Faner R. COPD 2020: changes and challenges. Am J Physiol Lung Cell Mol Physiol. 2020;319(5):L879–L883. doi:10.1152/ajplung.00429.2020
   PubMed Web of Science ®Google Scholar
• Valipour A, Aisanov Z, Avdeev S, et al. Recommendations for COPD management in Central and Eastern Europe. Expert Rev Respir Med. 2022;16(2):221–234.
   PubMed Web of Science ®Google Scholar
• Chai C-S, Liam C-K, Pang Y-K, et al. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2019;14:565–573. doi:10.2147/COPD.S196109
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Roman-Rodriguez M, Ribera X, Ritz J, Izquierdo JL; Opti Investigator's Group. Inhaled corticosteroid use among COPD patients in primary care in Spain. Int J Chron Obstruct Pulmon Dis. 2022;17:245–258. doi:10.2147/COPD.S342220
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC
   PubMed Web of Science ®Google Scholar
• Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):3–12. doi:10.2147/COPD.S85976
   PubMedGoogle Scholar
• Dal Negro RW, Carone M, Cuttitta G, et al. Prevalence and clinical features of most frequent phenotypes in the Italian COPD population: the CLIMA Study. Multidiscip Respir Med. 2021;16(1):790. doi:10.4081/mrm.2021.790
   PubMedGoogle Scholar
• Marques A, Souto-Miranda S, Machado A, et al. COPD profiles and treatable traits using minimal resources: identification, decision tree and stability over time. RespirRes. 2022;23(1):30.
   Google Scholar